Irinotecan ((+)-Irinotecan,伊立替康) - 仅供科研 |...

来自 : 发布时间：2024-05-10

请完善您的信息，提交审核升级会员，查看Irinotecan的详细信息 完成审核- 升级您的专属账户 即刻兑换价值 500 积分的多种礼券 根据当地政策法规的要求，该产品仅对科研客户提供相关信息。 您需要登录/注册您的专属账户，或与客服人员直接联系 确认您的产品用途，通过审核后，即可查看MCE会员专属产品。 Irinotecan ((+)-Irinotecan) 是一种拓扑异构酶 I (topoisomerase I) 抑制剂，可用于结肠癌和直肠癌的研究。 1.客户无需承担相应的运输费用。 2.同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内 可免费申领三个不同产品的试用装。 3.试用装只面向终端客户。 (a) CPT-11 induces cell cycle arrest and apoptosis in RAW 264.7macrophages. a.Western blot analysis of cleaved caspase-3 and PARP levels. (b) CPT-11 induced cell cycle arrest and apoptosis in mouse peritoneal macrophages. Western blot analysis of cleaved caspase-3 and PARP levels in peritoneal macrophages isolated from vehicleand CPT-11-administered mice. (c) Caspase-3 inhibitor z-DEVD-fmk (ZD) attenuates CPT-11-induced loss of GATA6+ peritoneal macrophages in mice. Western blot analy Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1]. Irinotecan is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 请依序添加每种溶剂：10% DMSO40% PEG3005% Tween-8045% salineSolubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution 此方案可获得 ≥ 2.08 mg/mL (3.55 mM，饱和度未知) 的澄清溶液。以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液 请依序添加每种溶剂：10% DMSO90% (20% SBE-β-CD in saline)Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution 此方案可获得 ≥ 2.08 mg/mL (3.55 mM，饱和度未知) 的澄清溶液。以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明 请依序添加每种溶剂：10% DMSO90% corn oilSolubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution 此方案可获得 ≥ 2.08 mg/mL (3.55 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 Exponentially growing cells are seeded in 20 cm2 dishes with an optimal cell number for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells, 40 h for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 Keywords: Irinotecan(+)-Irinotecan CPT-11CPT11CPT 11CPT-11TopoisomeraseAutophagyInhibitorinhibitorinhibit Please fill out this form to request the QC report. We will send it to your Email address shortly. Your information is safe with us. * Required Fields. MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。 站点地图 隐私声明